.png){kind=icon}
.png){kind=icon}
Return
Precision targeting of STING: challenges, innovations, and clinical outlook for cancer therapy
.png){kind=icon}
OA
AI
DOI：10.1016/j.xinn.2025.101074.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
■ The stimulator of interferon genes (STING) agonists have yet to demonstrate durable clinical efficacy. ■ Drug limitations, tumor heterogeneity, and immune suppression contribute to treatment resistance. ■ Drug delivery, molecular design, and combination strategies offer promising clinical translation avenues. ■ This review outlines the barriers to STING activation and the strategies for STING-targeted immunotherapy.
Keywords:
STING
cancer
immunotherapy
clinical translation
resistance
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
25.7
Papers:
875
Citations:
9.3K
View more organizations